Standard Therapy for Patients With Myelodysplastic Syndromes

被引：3

作者：

Al-Ameri, Ali

Cherry, Mohamad ^{[2
]}

Garcia-Manero, Guillermo

Quintas-Cardama, Alfonso ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA

[2] Univ Oklahoma, Hlth Sci Ctr, Dept Internal Med, Hematol Oncol Sect, Oklahoma City, OK USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2011年 / 11卷 / 04期

关键词：

Azacitidine; Decitabine; Lenalidomide; MDS; Myelodysplastic syndrome; ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; COLONY-STIMULATING FACTOR; LOW-DOSE 5-AZA-2'-DEOXYCYTIDINE; FARNESYL TRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITORS; BONE-MARROW-TRANSPLANTATION; PROGNOSTIC SCORING SYSTEM; IRON CHELATION-THERAPY; PHASE-II TRIAL;

D O I：

10.1016/j.clml.2011.06.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by cytopenias, dysplastic changes in the hematopoietic precursors, and an increased risk of evolving into acute leukemia. Treatment for patients with MDS ranges from supportive care with blood products and/or growth factors up to allogeneic stem cell transplantation. Over the past decade, several novel therapeutic agents have been approved for clinical use. In this article, the current approach for the management of patients with MDS according to their risk category is described and mainly focuses on approved novel agents.

引用

页码：303 / 313

页数：11

共 87 条

[41] Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia [J].

Kantarjian, Hagop ;

Oki, Yasuhiro ;

Garcia-Manero, Guillermo ;

Huang, Xuelin ;

O'Brien, Susan ;

Cortes, Jorge ;

Faderl, Stefan ;

Bueso-Ramos, Carlos ;

Ravandi, Farhad ;

Estrov, Zeev ;

Ferrajoli, Alessandra ;

Wierda, William ;

Shan, Jianqin ;

Davis, Jan ;

Giles, Francis ;

Saba, Hussain I. ;

Issa, Jean-Pierre J. .

BLOOD, 2007, 109 (01) :52-57

[42] Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy [J].

Kantarjian, Hagop M. ;

Giles, Francis J. ;

Greenberg, Peter L. ;

Paquette, Ron L. ;

Wang, Eunice S. ;

Gabrilove, Janice L. ;

Garcia-Manero, Guillermo ;

Hu, Kuolung ;

Franklin, Janet L. ;

Berger, Dietmar P. .

BLOOD, 2010, 116 (17) :3163-3170

[43]

Kantarjian Hagop M, 2007, Clin Adv Hematol Oncol, V5, P140

[44] Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression [J].

Kochenderfer, JN ;

Kobayashi, S ;

Wieder, ED ;

Su, CL ;

Molldrem, JJ .

BLOOD, 2002, 100 (10) :3639-3645

[45] TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia [J].

Kosmider, Olivier ;

Gelsi-Boyer, Veronique ;

Ciudad, Marion ;

Racoeur, Cindy ;

Jooste, Valerie ;

Vey, Norbert ;

Quesnel, Bruno ;

Fenaux, Pierre ;

Bastie, Jean-Noel ;

Beyne-Rauzy, Odile ;

Stamatoulas, Aspasia ;

Dreyfus, Francois ;

Ifrah, Norbert ;

de Botton, Stephane ;

Vainchenker, William ;

Bernard, Oliver A. ;

Birnbaum, Daniel ;

Fontenay, Michaela ;

Solary, Eric .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (12) :1676-1681

[46] TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) [J].

Kosmider, Olivier ;

Gelsi-Boyer, Veronique ;

Cheok, Meyling ;

Grabar, Sophie ;

Della-Valle, Veronique ;

Picard, Francoise ;

Viguie, Franck ;

Quesnel, Bruno ;

Beyne-Rauzy, Odile ;

Solary, Eric ;

Vey, Norbert ;

Hunault-Berger, Mathilde ;

Fenaux, Pierre ;

Mansat-De Mas, Veronique ;

Delabesse, Eric ;

Guardiola, Philippe ;

Lacombe, Catherine ;

Vainchenker, William ;

Preudhomme, Claude ;

Dreyfus, Francois ;

Bernard, Olivier A. ;

Birnbaum, Daniel ;

Fontenay, Michaela .

BLOOD, 2009, 114 (15) :3285-3291

[47] Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia [J].

Kuendgen, A ;

Knipp, S ;

Fox, F ;

Strupp, C ;

Hildebrandt, B ;

Steidl, C ;

Germing, U ;

Haas, R ;

Gattermann, N .

ANNALS OF HEMATOLOGY, 2005, 84 (Suppl 1) :61-66

[48] Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome [J].

Kurzrock, R ;

Albitar, M ;

Cortes, JE ;

Estey, EH ;

Faderl, SH ;

Garcia-Manero, G ;

Thomas, DA ;

Giles, FJ ;

Ryback, ME ;

Thibault, A ;

De Porre, P ;

Kantarjian, HM .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1287-1292

[49] Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting [J].

Kurzrock, R ;

Kantarjian, HM ;

Cortes, JE ;

Singhania, N ;

Thomas, DA ;

Wilson, EF ;

Wright, JJ ;

Freireich, EJ ;

Talpaz, M ;

Sebti, SM .

BLOOD, 2003, 102 (13) :4527-4534

[50] Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy [J].

Leitch, Heather A. .

LEUKEMIA RESEARCH, 2007, 31 :S7-S9

← 1 2 3 4 5 6 7 8 9 →